Cell Therapy Manufacturing market has gained significant attention in the overall biopharmaceutical industry. The personalized nature of these cell therapies options render them highly specific and, according to a number of clinical studies, safe and efficacious. Around 20 such therapies have been approved so far; recent approvals include Alofisel® (2018), YESCARTA® (2017) and Kymriah® (2017). It is also worth highlighting that over 500 therapy candidates are in different stages of clinical development by cell therapy manufacturing companies and are being evaluated in more than 1,000 active clinical studies across various regions of the globe. The growing number of cell therapy candidates, coupled to their rapid progression through various phases of clinical development, continues to create an increasing demand for facilities that offer cell therapy manufacturing services for these complex therapies.
Presently, over 145 organizations are actively involved in the GMP manufacturing of various types of genetically modified cells that are intended for therapeutic use.
The competitive landscape features the presence of industry and non-industry players, having the capability to produce various types of cell therapies including CAR T cell therapy at different scales of operation
Stem cells and immune cells are presently the major focus; there are many T-cell based candidates under development, most of which are in clinical stages.
The installed global cell therapy manufacturing capacity is currently estimated to be around 1.1 billion square feet; this capacity is well distributed across various geographies.
The US and EU, with relatively more number of manufacturing facilities, are the key hubs for cell-based therapy production.
Over 150 partnerships indicate an increasing activity in this domain; players are actively entering into collaborations focused on diverse types of cell therapies
Integration of automation technologies is anticipated to further augment production processes, offering favorable bench-to-clinic timelines and making such therapies more affordable.
Overall, the market is poised to grow at a steady pace and has over USD 8 billion potential; the opportunity is likely to be spread across different types of cell therapies.
In the short-term, clinical products will drive the market; however, in the long term, backed by commercial scale production, the US and EU are likely to capture over 75% share
Arun is an enthusiastic professional and has been associated with Roots Analysis since the very early years. He has led multifaceted roles over the years be it business research, consulting, competitive intelligence, IT & technology, sales and marketing. He currently drives strategic thinking and execution within the sales and marketing domain. With educational background in life sciences from Thapar University and digital marketing credentials from Indian School of Business, he has led a lot of critical initiatives at the organization. His background in life sciences has been one of the key reasons for quick understanding and implementation of customized marketing strategies. During his early years, he has led multiple consulting assignments for global clients ranging from competitive landscaping, deal structuring and preparing go-to-market strategy for his clients.